This trial is active, not recruiting.

Condition liver tumors
Treatments placebo, adenosine, liver resection
Phase phase 1/phase 2
Sponsor Ludwig-Maximilians - University of Munich
Trial identifier NCT00845689, LMU-202-LTR


Liver damage as a consequnce of ischemia (I) and reperfusion (R) is known to harm the liver and could hence be a critical factor of the postoperative outcome of patients undergoing liver surgery. In order to protect the liver from ischemic damage following interventions such as the Pringle Maneuver, preconditioning has been successfully applied in various animal models as well as in humans. Since ischemia inevitably leads to cell hypoxia and subsequnet release of endogenuous metabolites, the investigators hypothesize that instead of brief periods of ischemia, the exogenuous infusion of purine analogues may also protect against subsequent prolonged periods of ischemia. Moreover, after reperfusion, the antiinflamamtory action of purine ananlogue infusion can further attenuated liver damage.

United States No locations recruiting
Other countries No locations recruiting

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - elective resection of liver tumors - age 18 to 80 years - informed consent Exclusion Criteria: - chronic obstructive pulmonary disease - heart insufficiency NYHA III-IV - atrio-ventricular conductance blockage II. (Mobitz) or III. degree - atrial fibrillation - coronary heart disease (CCS III. or IV. degree) - arterial hypertension - acute renal failure - increased intracranial pressure - gout - pregnancy

Additional Information

Official title Study on the Potential Role of Intraoperative Hepatoprotection During Liver Resections
Trial information was received from ClinicalTrials.gov and was last updated in February 2009.
Information provided to ClinicalTrials.gov by Ludwig-Maximilians - University of Munich.